DMC Biotechnologies Closes $34M First Close of Series B Funding - FinSMEs

Uncategorized

DMC Biotechnologies Closes $34M First Close of Series B Funding – FinSMEs

Home » DMC Biotechnologies Closes $34M First Close of Series B Funding

REAL TIME VC & PRIVATE EQUITY DEALS AND NEWS
DMC Biotechnologies, a Boulder, CO and Durham, NC-based biobased chemical company that makes products using microbial fermentation, completed the first close of its Series B fundraising, raising $34m (USD).
Backers included Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin.
Led by Matt Lipscomb, Ph.D., CEO & Co-Founder, DMC provides a bio-based chemical intermediate with primary applications in home care and human nutrition and has a deep pipeline of predictable, scalable, cost-competitive products, addressing sustainability challenges across a wide range of industries, including animal nutrition, human nutrition, personal and home care, and a broad range of chemical intermediates.
The company’s proprietary technology simplifies biology and makes fermentation more predictable and efficient.
FinSMEs
03/12/2021
Email address:

Privacy Policy (function (w,d) {var loader = function () {var s = d.createElement(“script”), tag = d.getElementsByTagName(“script”)[0]; s.src = “https://cdn.iubenda.com/iubenda.js”; tag.parentNode.insertBefore(s,tag);}; w.addEventListener ? w.addEventListener(“load”, loader, false) : w.attachEvent(“onload”, loader);})(window, document); FinSMEs is owned by FinSMEs Ltd – 86 – 90 Paul Street – London, UK – EC2A 4NE – e-mail: [email protected]
Follow FinSMEs on:

source